Alto Neuroscience (ANRO) Operating Expenses (2023 - 2026)

Alto Neuroscience (ANRO) has 4 years of Operating Expenses data on file, last reported at $27.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 73.12% year-over-year to $27.1 million; the trailing twelve-month figure through Mar 2026 stood at $77.8 million (up 11.34% YoY), and the FY2025 full-year result was $66.4 million, down 3.27% from the prior year.
• Operating Expenses grew to $27.1 million in Q1 2026, from $17.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $27.1 million in Q1 2026 to a low of $7.2 million in Q1 2023.
• A 4-year average of $15.4 million and a median of $15.7 million in 2025 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses soared 101.0% in 2024 and decreased 20.84% in 2025, its largest moves.
• Tracing ANRO's Operating Expenses over 4 years: stood at $11.8 million in 2023, then soared by 44.47% to $17.0 million in 2024, then climbed by 0.34% to $17.1 million in 2025, then soared by 59.12% to $27.1 million in 2026.
• Business Quant data shows ANRO's Operating Expenses at $27.1 million in Q1 2026, $17.1 million in Q4 2025, and $15.0 million in Q3 2025.